Filtered By:
Condition: Diabetes
Therapy: Statin Therapy
This page shows you your search results in order of relevance. This is page number 18.
Order by Relevance | Date
Total 723 results found since Jan 2013.
2017 Taiwan lipid guidelines for high risk patients
Publication date: Available online 24 February 2017 Source:Journal of the Formosan Medical Association Author(s): Yi-Heng Li, Kwo-Chang Ueng, Jiann-Shing Jeng, Min-Ji Charng, Tsung-Hsien Lin, Kuo-Liong Chien, Chih-Yuan Wang, Ting-Hsing Chao, Ping-Yen Liu, Cheng-Huang Su, Shih-Chieh Chien, Chia-Wei Liou, Sung-Chun Tang, Chun-Chuan Lee, Tse-Ya Yu, Jaw-Wen Chen, Chau-Chung Wu, Hung-I Yeh In Taiwan, the prevalence of hyperlipidemia increased due to lifestyle and dietary habit changes. Low density lipoprotein cholesterol (LDL-C) and non-high density lipoprotein cholesterol (non-HDL-C) are all significant predicting factors of ...
Source: Journal of the Formosan Medical Association - February 24, 2017 Category: Journals (General) Source Type: research
2017 Taiwan lipid guidelines for high risk patients.
Abstract
In Taiwan, the prevalence of hyperlipidemia increased due to lifestyle and dietary habit changes. Low density lipoprotein cholesterol (LDL-C) and non-high density lipoprotein cholesterol (non-HDL-C) are all significant predicting factors of coronary artery disease in Taiwan. We recognized that lipid control is especially important in patients with existed atherosclerotic cardiovascular diseases (ASCVD), including coronary artery disease (CAD), ischemic stroke and peripheral arterial disease (PAD). Because the risk of ASCVD is high in patients with diabetes mellitus (DM), chronic kidney disease (CKD) and f...
Source: J Formos Med Assoc - February 23, 2017 Category: Journals (General) Authors: Li YH, Ueng KC, Jeng JS, Charng MJ, Lin TH, Chien KL, Wang CY, Chao TH, Liu PY, Su CH, Chien SC, Liou CW, Tang SC, Lee CC, Yu TY, Chen JW, Wu CC, Yeh HI, Writing Group of 2017 Taiwan Lipid Guidelines for High Risk Patients Tags: J Formos Med Assoc Source Type: research
Prognostic Analysis for Cardiogenic Shock in Patients with Acute Myocardial Infarction Receiving Percutaneous Coronary Intervention.
Abstract
Cardiogenic shock (CS) is uncommon in patients suffering from acute myocardial infarction (AMI). Long-term outcome and adverse predictors for outcomes in AMI patients with CS receiving percutaneous coronary interventions (PCI) are unclear. A total of 482 AMI patients who received PCI were collected, including 53 CS and 429 non-CS. Predictors for AMI patients with CS including recurrent MI, cardiovascular (CV) mortality, all-cause mortality, and repeated-PCI were analyzed. The CS group had a lower central systolic pressure and central diastolic pressure (both P < 0.001). AMI patients with hypertension h...
Source: Biomed Res - March 4, 2017 Category: Research Authors: Lin MJ, Chen CY, Lin HD, Wu HP Tags: Biomed Res Int Source Type: research
Rationale and design of REDUCE ‐IT: Reduction of Cardiovascular Events with Icosapent Ethyl–Intervention Trial
Residual cardiovascular risk persists despite statins, yet outcome studies of lipid‐targeted therapies beyond low‐density lipoprotein cholesterol (LDL‐C) have not demonstrated added benefit. Triglyceride elevation is an independent risk factor for cardiovascular events. High‐dose eicosapentaenoic acid (EPA) reduces triglyceride‐rich lipoproteins without raising LDL‐C. Omega‐3s have postulated pleiotropic cardioprotective benefits beyond triglyceride‐lowering. To date, no large, multinational, randomized clinical trial has proved that lowering triglycerides on top of statin therapy improves cardiovascular ou...
Source: Clinical Cardiology - March 14, 2017 Category: Cardiology Authors: Deepak L. Bhatt, Ph. Gabriel Steg, Eliot A. Brinton, Terry A. Jacobson, Michael Miller, Jean ‐Claude Tardif, Steven B. Ketchum, Ralph T. Doyle, Sabina A. Murphy, Paresh N. Soni, Rene A. Braeckman, Rebecca A. Juliano, Christie M. Ballantyne, Tags: TRIAL DESIGNS Source Type: research
Use of Lipid-Modifying Therapy and LDL-C Goal Attainment in a High-Cardiovascular-Risk Population in the Netherlands.
This study investigates lipid-modifying therapy (LMT) and LDL-C goal attainment in a real-world, high-cardiovascular-risk population in the Netherlands.
METHODS: From the PHARMO Database Network, patients aged ≥18 years with an LDL-C measurement in 2012 (index date) were selected and hierarchically classified into the following mutually exclusive high-cardiovascular-risk categories: familial hypercholesterolemia (FH), recent acute coronary syndrome (ACS), coronary heart disease, ischemic stroke, peripheral arterial disease, and diabetes mellitus. LMT use and LDL-C goal attainment at the index date was assessed.
...
Source: Clinical Therapeutics - March 24, 2017 Category: Drugs & Pharmacology Authors: Kuiper JG, Sanchez RJ, Houben E, Heintjes EM, Penning-van Beest FJ, Khan I, van Riemsdijk M, Herings RM Tags: Clin Ther Source Type: research
Economic evaluation of ezetimibe treatment in combination with statin therapy in the United States.
CONCLUSIONS: Compared with statin monotherapy, ezetimibe with statin therapy was cost-effective for secondary prevention of CHD and stroke and for primary prevention of these conditions in patients whose LDL-C level is ≥ 100 mg/dL and in patients with diabetes, taking into account a 90% cost reduction for ezetimibe.
PMID: 28426345 [PubMed - as supplied by publisher]
Source: Journal of Medical Economics - April 22, 2017 Category: Health Management Tags: J Med Econ Source Type: research
Effect of Addition of a Statin to Warfarin on Thromboembolic Events in Japanese Patients With Nonvalvular Atrial Fibrillation and Diabetes Mellitus
Statins have been shown to decrease stroke risk in patients with cardiovascular risk factors, but not to prevent recurrence of ischemic stroke in patients with atrial fibrillation (AF). The present subanalysis aimed to clarify the efficacy of combined use of warfarin and statins in nonvalvular AF (NVAF) patients with coronary artery disease (CAD), diabetes mellitus (DM) or hypertension. The effects of adding statins to warfarin were compared with those of warfarin alone in NVAF patients with the data set of J-RHYTHM Registry, a prospective, observational study with a 2-year follow-up.
Source: The American Journal of Cardiology - April 26, 2017 Category: Cardiology Authors: Naoko Kumagai, John A. Nusser, Hiroshi Inoue, Ken Okumura, Takeshi Yamashita, Toru Kubo, Hiroaki Kitaoka, Hideki Origasa, Hirotsugu Atarashi, J-RHYTHM Registry Investigators Source Type: research
Beta-blockers 'useless' for many heart attack patients, study reports
Conclusion
This study aimed to see whether beta blockers reduce mortality in people who've had a heart attack but who don't have heart failure or systolic dysfunction. It found no difference between those who were and those who were not given beta-blockers on discharge from hospital.
The authors say this adds to the evidence that routine prescription of beta blockers might not be needed for patients without heart failure following a heart attack.
Current UK guidelines recommend all people who have had a heart attack take beta blockers for at least one year to reduce risk of recurrent events. Only people with heart failure ...
Source: NHS News Feed - May 30, 2017 Category: Consumer Health News Tags: Heart/lungs Medication Source Type: news
Dyslipidemia management in patients with high cardiovascular risk in Spain. ALMA study.
CONCLUSIONS: Although CVR assessment is generally accepted, there is broad disagreement in defining the objectives of LDL-C. Most often than PCPs, the SCPs consider more ambitious targets for LDL-C and the association of lipid-lowering drugs.
PMID: 28619533 [PubMed - as supplied by publisher]
Source: Atencion Primaria - June 12, 2017 Category: Primary Care Authors: Pintó X, Trias Vilagut F, Rius Taruella J, Mairal Sallán E Tags: Aten Primaria Source Type: research
Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial
Publication date: Available online 15 September 2017 Source:The Lancet Diabetes & Endocrinology Author(s): Marc S Sabatine, Lawrence A Leiter, Stephen D Wiviott, Robert P Giugliano, Prakash Deedwania, Gaetano M De Ferrari, Sabina A Murphy, Julia F Kuder, Ioanna Gouni-Berthold, Basil S Lewis, Yehuda Handelsman, Armando Lira Pineda, Narimon Honarpour, Anthony C Keech, Peter S Sever, Terje R Pedersen Background The proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor evolocumab reduced LDL cholesterol and cardiovascular events in the FOURIER trial. In this prespecified analysis of FOURIER, we investigated ...
Source: The Lancet Diabetes and Endocrinology - September 16, 2017 Category: Endocrinology Source Type: research
Management and clinical outcome of stable coronary artery disease in Austria : Results from 5 years of the CLARIFY registry.
CONCLUSION: Characteristics of Austrian outpatients with stable CAD corresponded to those of patients with CAD in other developed countries. Medical treatments following the recommendations of the European guidelines were prescribed in the majority of patients; however, recommended goals of life style interventions including a heart rate less than 60 bpm and general risk factor management were not achieved by a high proportion of patients. Heart rate control and life style changes remain unmet needs of cardiovascular care in Austria.
PMID: 28913755 [PubMed - as supplied by publisher]
Source: Wiener Klinische Wochenschrift - September 14, 2017 Category: General Medicine Authors: Lang IM, Badr-Eslam R, Greenlaw N, Young R, Steg PG Tags: Wien Klin Wochenschr Source Type: research
Mechanisms, Clinical Significance and Prevention of Cognitive Impairment in Atrial Fibrillation
Publication date: Available online 6 October 2017 Source:Canadian Journal of Cardiology Author(s): Lena Rivard, Paul Khairy Atrial fibrillation (AF) and dementia are major health issues, with growing evidence suggesting a consistent association between AF and all forms of dementia. Although dementia and AF share several risk factors, the association appears to be independent of a history of clinical stroke and other comorbidities such as hypertension, heart failure, and diabetes. Proposed mechanisms linking AF to cognitive decline include altered hemodynamics resulting in cerebral hypoperfusion, inflammation, genetic fact...
Source: Canadian Journal of Cardiology - October 7, 2017 Category: Cardiology Source Type: research
HIV-positive adults are under-treated for cardiovascular problems compared to those without HIV
This study provides evidence that U.S. policymakers and professional societies should focus on improving the quality of the cardiovascular care that people who are HIV-positive receive.AUTHORSStudy authors are Dr. Joseph Ladapo, Dr. Adam Richards, Cassandra DeWitt, Nina Harawa, Steven Shoptaw, Dr. William Cunningham and Dr. John Mafi, all of UCLA. Mafi is also associated with Rand Corporation.JOURNALThestudy is published in the Journal of the American Heart Association.FUNDINGGrants from the National Heart, Lung and Blood Institute, National Institute on Minority Health and Health Disparities, and National Institute of Men...
Source: UCLA Newsroom: Health Sciences - November 22, 2017 Category: Universities & Medical Training Source Type: news
Pharmacologic Interventions to Prevent Cognitive Decline, Mild Cognitive Impairment, and Clinical Alzheimer-Type Dementia: A Systematic Review.
Conclusion: Evidence does not support use of the studied pharmacologic treatments for cognitive protection in persons with normal cognition or MCI.
Primary Funding Source: Agency for Healthcare Research and Quality.
PMID: 29255847 [PubMed - as supplied by publisher]
Source: Annals of Internal Medicine - December 19, 2017 Category: Internal Medicine Authors: Fink HA, Jutkowitz E, McCarten JR, Hemmy LS, Butler M, Davila H, Ratner E, Calvert C, Barclay TR, Brasure M, Nelson VA, Kane RL Tags: Ann Intern Med Source Type: research
Statin Safety: What Every Health Care Provider Needs to Know
AbstractPurpose of ReviewA key target for quality improvement in preventive cardiology is statin therapy, which is underutilized in appropriate high-risk patients for LDL-lowering to prevent atherosclerotic cardiovascular disease events. Translation of statin evidence to practice may be impeded by exaggerated concerns about adverse effects. We aim to cut through an immense amount of controversy in the scientific and mainstream discourse of statin safety by clearly demarcating the reported adverse events based on the reliability of the supporting evidence.Recent FindingsIn large-scale randomized controlled trials, statin th...
Source: Current Cardiovascular Risk Reports - January 22, 2018 Category: Cardiology Source Type: research
